* 中国生物科技公司信达生物1801.HK周一盘中一度升2.3%。
* 该公司此前公告称，信必敏（替妥尤单抗N01注射液）的新药上市申请获中国国家药品监督管理局批准上市，用于治疗甲状腺眼病。这是一种器官特异自身免疫性疾病，引起眼球突出、复视等临床表现，严重的可导致失明。
* 信达生物今年迄今涨11.9%，同期恒生指数.HSI上扬21%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升1.1%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.